https://doi.org/10.1016/j.nmni.2020.100710
Abstract
Fundings and gifts from the pharmaceutical industry
have an influence on the decisions made by physicians and medical
experts. In the context of the COVID-19 epidemic, several treatments are
available to treat patients infected with the virus. Some are protected
by patents, such as remdesivir, others are not, such as
hydroxychloroquine. We wanted to observe the possible correlation
between the fact, for an academic doctor in infectious diseases, of
having benefited from funding by Gilead Sciences, producer of
remdesivir, and the public positions taken by this doctor towards
hydroxychloroquine. Our results show a correlation (correlation
coefficient = 1) between the amount received from the Gilead Sciences
company and public opposition to the use of hydroxychloroquine in
France. This should open up the debate on the role of the interest links
of doctors with pharmaceutical companies in the medical and scientific
public debate.
https://www.sciencedirect.com/science/article/pii/S2052297520300627
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.